Xiaojun Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Xiaojun Zhou has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
- Chuanglong He
State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, 201620, PR China
34 shared publications Tao Li
Department of Orthopaedics
12 shared publicationsShuo Chen
State Key Laboratory for Advanced Fiber Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Biological Science and Medical Engineering, Donghua University, Shanghai, 201620, China
10 shared publicationsJin Yang
State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, 201620, PR China
9 shared publicationsHaibo Du
State Key Laboratory for Modification of Chemical Fibers and Polymer Materials, College of Chemistry, Chemical Engineering and Biotechnology, Donghua University, Shanghai, 201620, PR China
6 shared publicationsGuang Yang
State Key Laboratory of Advanced Fiber Materials, Shanghai Engineering Research Center of Nano-Biomaterials and Regenerative Medicine, College of Biological Science and Medical Engineering, Donghua University, Shanghai, 201620, China
5 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Immunomodulatory 3D-printed conductive scaffold combined with electrostimulation: a dual-strategy approach to enhance bone regeneration
Conventional conductive scaffolds lack the capacity to dynamically coordinate the immuno-osteogenic coupling that is critical for effective bone repair. In
- 29 July 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessImmunomodulatory 3D-printed conductive scaffold combined with electrostimulation: a dual-strategy approach to enhance bone regeneration
Conventional conductive scaffolds lack the capacity to dynamically coordinate the immuno-osteogenic coupling that is critical for effective bone repair. In
- Open Access
- 4 March 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102988
Programmed regulation of microenvironment remodeling and bone regeneration for bone repair by coaxial hydrogel scaffold with ultrasound-activated drug delivery
- 4 March 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102988
Open AccessProgrammed regulation of microenvironment remodeling and bone regeneration for bone repair by coaxial hydrogel scaffold with ultrasound-activated drug delivery
- Open Access
- 21 January 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102837
Synergistic 3D-bioprinted scaffold with multi-level adaptability for vascularized bone regeneration via osteogenesis-angiogenesis coupling
- 21 January 2026
- Published by Elsevier in Materials Today Bio
- Vol. 37, 102837
Open AccessSynergistic 3D-bioprinted scaffold with multi-level adaptability for vascularized bone regeneration via osteogenesis-angiogenesis coupling
- 1 July 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (28) , 40035-40051
NIR-Activatable Antibacterial 3D-Printed Hydrogel Scaffold with Controllable Drug Release for Enhanced Vascularized Bone Regeneration
Three-dimensional (3D)-printed scaffolds have been extensively researched in the field of tissue engineering for their exceptional biocompatibility as well as precise regenerative capabilities. However, developing photothermal-responsive scaffolds that exhibit near-infrared (NIR)-activatable mechanical shrinkage for controlled and highly sensitive drug release remains a significant challenge in achieving efficient and rapid bone repair. In this article, we designed a 3D-printed hydrogel scaffold (DFO-Au@GN) composed of deferoxamine (DFO)-loaded gold nanoparticles (AuNPs), gelatin methacrylate (GelMA), and N-isopropylacrylamide (NIPAM) to promote superior vascularized osteogenesis. The AuNPs were synthesized in a single step using gelatin as both the reducing agent and stabilizer, which not only demonstrated high drug loading efficiency but also imparted excellent photothermal conversion performance, mechanical and osteogenic properties to the scaffold. The composite scaffold exhibited a shrinkage property when irradiated by 808 nm NIR light, facilitating the controlled release of DFO and AuNPs. In vitro studies indicated that the heat generated by AuNPs effectively eradicated bacteria, thereby addressing the early infections associated with scaffold implantation. Additionally, the DFO-Au@GN scaffold efficiently stimulated angiogenesis from the activation of the hypoxia-inducible factor 1α (HIF-1α) signaling pathway and enhanced the ossification of bone marrow mesenchymal stem cells (BMSCs). The multifunctional scaffold was further demonstrated to significantly improve the repair efficiency of rat calvarial defects through the combined influence of mild thermal stimulation and biochemical induction and promote the formation of H-type vessels for the coupling of angiogenesis and osteogenesis from the results of animal experiments. Therefore, the DFO-Au@GN scaffold, in conjunction with NIR-triggered mild heat stimulation, holds considerable promise for the efficient and rapid treatment of bone defects.
- 1 July 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (28) , 40035-40051
NIR-Activatable Antibacterial 3D-Printed Hydrogel Scaffold with Controllable Drug Release for Enhanced Vascularized Bone Regeneration
Three-dimensional (3D)-printed scaffolds have been extensively researched in the field of tissue engineering for their exceptional biocompatibility as well as precise regenerative capabilities. However, developing photothermal-responsive scaffolds that exhibit near-infrared (NIR)-activatable mechanical shrinkage for controlled and highly sensitive drug release remains a significant challenge in achieving efficient and rapid bone repair. In this article, we designed a 3D-printed hydrogel scaffold (DFO-Au@GN) composed of deferoxamine (DFO)-loaded gold nanoparticles (AuNPs), gelatin methacrylate (GelMA), and N-isopropylacrylamide (NIPAM) to promote superior vascularized osteogenesis. The AuNPs were synthesized in a single step using gelatin as both the reducing agent and stabilizer, which not only demonstrated high drug loading efficiency but also imparted excellent photothermal conversion performance, mechanical and osteogenic properties to the scaffold. The composite scaffold exhibited a shrinkage property when irradiated by 808 nm NIR light, facilitating the controlled release of DFO and AuNPs. In vitro studies indicated that the heat generated by AuNPs effectively eradicated bacteria, thereby addressing the early infections associated with scaffold implantation. Additionally, the DFO-Au@GN scaffold efficiently stimulated angiogenesis from the activation of the hypoxia-inducible factor 1α (HIF-1α) signaling pathway and enhanced the ossification of bone marrow mesenchymal stem cells (BMSCs). The multifunctional scaffold was further demonstrated to significantly improve the repair efficiency of rat calvarial defects through the combined influence of mild thermal stimulation and biochemical induction and promote the formation of H-type vessels for the coupling of angiogenesis and osteogenesis from the results of animal experiments. Therefore, the DFO-Au@GN scaffold, in conjunction with NIR-triggered mild heat stimulation, holds considerable promise for the efficient and rapid treatment of bone defects.
- Open Access
- 1 May 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 47, 528-530
Corrigendum to “Construction of nanofibrous scaffolds with interconnected perfusable microchannel networks for engineering of vascularized bone tissue” [Bioact. Mater. 6 (2021),3254–3268]
Schematic diagram of nanofibrous scaffolds with interconnected perfusable microchannel networks for engineering of vascularized bone tissue. Image 1
- 1 May 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 47, 528-530
Open AccessCorrigendum to “Construction of nanofibrous scaffolds with interconnected perfusable microchannel networks for engineering of vascularized bone tissue” [Bioact. Mater. 6 (2021),3254–3268]
Schematic diagram of nanofibrous scaffolds with interconnected perfusable microchannel networks for engineering of vascularized bone tissue. Image 1
- Open Access
- 1 May 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 47, 83-99
TME-responsive nanocomposite hydrogel with targeted capacity for enhanced synergistic chemoimmunotherapy of MYC-amplified osteosarcoma
The oncogene MYC is one of the most commonly activated oncogenic proteins in human tumors, with nearly one-fourth of osteosarcoma showing MYC amplification and exhibiting the worst clinical outcomes. The clinical efficacy of single radiotherapy, chemotherapy, and immunotherapy for such osteosarcoma is poor, and the dysregulation of MYC amplification and immune-suppressive tumor microenvironment (TME) may be potential causes of anti-tumor failure. To address the above issues, we developed an injectable TME-responsive nanocomposite hydrogel to simultaneously deliver an effective MYC inhibitor (NHWD-870) and IL11Rα-targeted liposomes containing cisplatin-loaded MnO2 (Cis/Mn@Lipo-IL11). After in situ administration, NHWD-870 effectively degrades MYC and downregulates CCL2 and IL13 cytokines to trigger M1 type activation of macrophages. Meanwhile, targeted delivery of Cis/Mn@Lipo-IL11 reacts with excess intratumoral GSH to generate Mn2+ and thus inducing excess active oxygen species (ROS) production through Fenton-like reaction, along with cisplatin, thereby inducing immunogenic cell death (ICD) to promote dendritic cell maturation. Through synergistic regulation of MYC and ICD levels, the immune microenvironment was reshaped to enhance immune infiltration. In the osteosarcoma-bearing model, the nanocomposite hydrogel significantly enhanced tumor T cell infiltration, induced effective anti-tumor immunity and attenuated lung metastasis. Therefore, our results reveal a powerful strategy for targeted combination therapy of MYC-amplified osteosarcoma.
- 1 May 2025
- Published by KEAI Publishing in Bioactive Materials
- Vol. 47, 83-99
Open AccessTME-responsive nanocomposite hydrogel with targeted capacity for enhanced synergistic chemoimmunotherapy of MYC-amplified osteosarcoma
The oncogene MYC is one of the most commonly activated oncogenic proteins in human tumors, with nearly one-fourth of osteosarcoma showing MYC amplification and exhibiting the worst clinical outcomes. The clinical efficacy of single radiotherapy, chemotherapy, and immunotherapy for such osteosarcoma is poor, and the dysregulation of MYC amplification and immune-suppressive tumor microenvironment (TME) may be potential causes of anti-tumor failure. To address the above issues, we developed an injectable TME-responsive nanocomposite hydrogel to simultaneously deliver an effective MYC inhibitor (NHWD-870) and IL11Rα-targeted liposomes containing cisplatin-loaded MnO2 (Cis/Mn@Lipo-IL11). After in situ administration, NHWD-870 effectively degrades MYC and downregulates CCL2 and IL13 cytokines to trigger M1 type activation of macrophages. Meanwhile, targeted delivery of Cis/Mn@Lipo-IL11 reacts with excess intratumoral GSH to generate Mn2+ and thus inducing excess active oxygen species (ROS) production through Fenton-like reaction, along with cisplatin, thereby inducing immunogenic cell death (ICD) to promote dendritic cell maturation. Through synergistic regulation of MYC and ICD levels, the immune microenvironment was reshaped to enhance immune infiltration. In the osteosarcoma-bearing model, the nanocomposite hydrogel significantly enhanced tumor T cell infiltration, induced effective anti-tumor immunity and attenuated lung metastasis. Therefore, our results reveal a powerful strategy for targeted combination therapy of MYC-amplified osteosarcoma.
- 17 March 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (12) , 17932-17947
Reprogramming Macrophage Phenotype Using a Reactive Oxygen Species-Responsive Liposome Delivery System for Inflammation Microenvironment Remodeling and Osteoarthritis Treatment
The progression of osteoarthritis (OA) is closely linked to synovial inflammation caused by an imbalance between M1 and M2 macrophages. To tackle this problem, we developed a liposome responsive to reactive oxygen species (ROS), modified with folic acid ligands to target M1-polarized macrophages, and loaded with the anti-inflammatory agent dimethyl fumarate (DMF). This liposome-based drug delivery system was designed to reprogram macrophage phenotype to remodel the inflammatory microenvironment in the joint cavity and alleviate OA degeneration. The liposome we prepared had a suitable size and negative zeta potential, with uniform size, good stability in aqueous solution, and excellent biocompatibility. Laboratory tests showed that these DMF-filled liposomes notably decreased high levels of ROS in M1-type macrophages and shifted macrophage polarization via the Nrf2/HO-1 pathway, which in turn lessened inflammation in chondrocytes and averted their apoptosis. Additionally, animal studies demonstrated that liposomes containing DMF exhibited notable anti-inflammatory properties, significantly reduced synovial inflammation, safeguarded injured cartilage, reversed changes in subchondral bone, and effectively slowed the progression of osteoarthritis in a mouse model induced by anterior cruciate ligament transection (ACLT). Therefore, ROS-responsive liposomes targeting M1-polarized macrophages represent a promising and valuable approach for OA treatment.
- 17 March 2025
- Published by American Chemical Society (ACS) in ACS Applied Materials & Interfaces
- Vol. 17 (12) , 17932-17947
Reprogramming Macrophage Phenotype Using a Reactive Oxygen Species-Responsive Liposome Delivery System for Inflammation Microenvironment Remodeling and Osteoarthritis Treatment
The progression of osteoarthritis (OA) is closely linked to synovial inflammation caused by an imbalance between M1 and M2 macrophages. To tackle this problem, we developed a liposome responsive to reactive oxygen species (ROS), modified with folic acid ligands to target M1-polarized macrophages, and loaded with the anti-inflammatory agent dimethyl fumarate (DMF). This liposome-based drug delivery system was designed to reprogram macrophage phenotype to remodel the inflammatory microenvironment in the joint cavity and alleviate OA degeneration. The liposome we prepared had a suitable size and negative zeta potential, with uniform size, good stability in aqueous solution, and excellent biocompatibility. Laboratory tests showed that these DMF-filled liposomes notably decreased high levels of ROS in M1-type macrophages and shifted macrophage polarization via the Nrf2/HO-1 pathway, which in turn lessened inflammation in chondrocytes and averted their apoptosis. Additionally, animal studies demonstrated that liposomes containing DMF exhibited notable anti-inflammatory properties, significantly reduced synovial inflammation, safeguarded injured cartilage, reversed changes in subchondral bone, and effectively slowed the progression of osteoarthritis in a mouse model induced by anterior cruciate ligament transection (ACLT). Therefore, ROS-responsive liposomes targeting M1-polarized macrophages represent a promising and valuable approach for OA treatment.
- 12 December 2024
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 11 (1) , 182-207
Advanced Bioresponsive Drug Delivery Systems for Promoting Diabetic Vascularized Bone Regeneration
The treatment of bone defects in diabetes mellitus (DM) patients remains a major challenge since the diabetic microenvironments significantly impede bone regeneration. Many abnormal factors including hyperglycemia, elevated oxidative stress, increased inflammation, imbalanced osteoimmune, and impaired vascular system in the diabetic microenvironment will result in a high rate of impaired, delayed, or even nonhealing events of bone tissue. Stimuli-responsive biomaterials that can respond to endogenous biochemical signals have emerged as effective therapeutic systems to treat diabetic bone defects via the combination of microenvironmental regulation and enhanced osteogenic capacity. Following the natural bone healing processes, coupling of angiogenesis and osteogenesis by advanced bioresponsive drug delivery systems has proved to be of significant approach for promoting bone repair in DM. In this Review, we have systematically summarized the mechanisms and therapeutic strategies of DM-induced impaired bone healing, outlined the bioresponsive design for drug delivery systems, and highlighted the vascularization strategies for promoting bone regeneration. Accordingly, we then overview the recent advances in developing bioresponsive drug delivery systems to facilitate diabetic vascularized bone regeneration by remodeling the microenvironment and modulating multiple regenerative cues. Furthermore, we discuss the development of adaptable drug delivery systems with unique features for guiding DM-associated bone regeneration in the future.
- 12 December 2024
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 11 (1) , 182-207
Advanced Bioresponsive Drug Delivery Systems for Promoting Diabetic Vascularized Bone Regeneration
The treatment of bone defects in diabetes mellitus (DM) patients remains a major challenge since the diabetic microenvironments significantly impede bone regeneration. Many abnormal factors including hyperglycemia, elevated oxidative stress, increased inflammation, imbalanced osteoimmune, and impaired vascular system in the diabetic microenvironment will result in a high rate of impaired, delayed, or even nonhealing events of bone tissue. Stimuli-responsive biomaterials that can respond to endogenous biochemical signals have emerged as effective therapeutic systems to treat diabetic bone defects via the combination of microenvironmental regulation and enhanced osteogenic capacity. Following the natural bone healing processes, coupling of angiogenesis and osteogenesis by advanced bioresponsive drug delivery systems has proved to be of significant approach for promoting bone repair in DM. In this Review, we have systematically summarized the mechanisms and therapeutic strategies of DM-induced impaired bone healing, outlined the bioresponsive design for drug delivery systems, and highlighted the vascularization strategies for promoting bone regeneration. Accordingly, we then overview the recent advances in developing bioresponsive drug delivery systems to facilitate diabetic vascularized bone regeneration by remodeling the microenvironment and modulating multiple regenerative cues. Furthermore, we discuss the development of adaptable drug delivery systems with unique features for guiding DM-associated bone regeneration in the future.
- 2 December 2024
- Published by Elsevier in Biomaterials
- Vol. 316, 122985
A super soft thermoplastic biodegradable elastomer with high elasticity for arterial regeneration
- 2 December 2024
- Published by Elsevier in Biomaterials
- Vol. 316, 122985
A super soft thermoplastic biodegradable elastomer with high elasticity for arterial regeneration